Local blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in cutaneous wound healing

Wound Repair and Regeneration

Volumn 21, Issue 5, 2013, Pages 715-722

  Youm, Jong Kyung ^a,b   Park, Kyungho ^a,b   Uchida, Yoshikazu ^a,b,c   Chan, Aegean ^a,b   Mauro, Theodora M ^a,b,c   Holleran, Walter M ^a,b,c   Elias, Peter M ^a,b,c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ANTALARMIN; CARBENOXOLONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GW 3695; HORMONE RECEPTOR STIMULATING AGENT; LIVER X RECEPTOR; MIFEPRISTONE; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SKIN BIOPSY; STRESS; WOUND HEALING IMPAIRMENT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DOWN-REGULATION; GLUCOCORTICOIDS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID; STRESS, PSYCHOLOGICAL; WOUND HEALING;

EID: 84883490770     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12083     Document Type: Article

References (41)

1. Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R,. Slowing of wound healing by psychological stress. Lancet 1995; 346: 1194-1196.
2. Marucha PT, Kiecolt-Glaser JK, Favagehi M,. Mucosal wound healing is impaired by examination stress. Psychosom Med 1998; 60: 362-365.
3. Padgett DA, Marucha PT, Sheridan JF,. Restraint stress slows cutaneous wound healing in mice. Brain Behav Immun 1998; 12: 64-73.
4. Altemus M, Rao B, Dhabhar FS, Ding W, Granstein RD,. Stress-induced changes in skin barrier function in healthy women. J Invest Dermatol 2001; 117: 309-317.
5. Garg A, Chren MM, Sands LP, Matsui MS, Marenus KD, Feingold KR, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol 2001; 137: 53-59.
6. Elias PM,. Defensive functions of the stratum corneum: integrative aspects. In:, Elias PM, Feingold KR, editors. Skin barrier. New York: Taylor & Francis, 2006: 5-14.
7. Suetake T, Sasai S, Zhen YX, Ohi T, Tagami H,. Functional analyses of the stratum corneum in scars. Sequential studies after injury and comparison among keloids, hypertrophic scars, and atrophic scars. Arch Dermatol 1996; 132: 1453-1458.
8. Denda M, Tsuchiya T, Hosoi J, Koyama J,. Immobilization-induced and crowded environment-induced stress delay barrier recovery in murine skin. Br J Dermatol 1998; 138: 780-785.
9. Denda M, Tsuchiya T, Elias PM, Feingold KR,. Stress alters cutaneous permeability barrier homeostasis. Am J Physiol Regul Integr Comp Physiol 2000; 278: R367-372.
10. Choi EH, Demerjian M, Crumrine D, Brown BE, Mauro T, Elias PM, et al. Glucocorticoid blockade reverses psychological stress-induced abnormalities in epidermal structure and function. Am J Physiol Regul Integr Comp Physiol 2006; 291: R1657-1662.
11. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-866.
12. Wamil M, Seckl JR,. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007; 12: 504-520.
13. Hammami MM, Siiteri PK,. Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 1991; 73: 326-334.
14. Hennebert O, Chalbot S, Alran S, Morfin R,. Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes. J Steroid Biochem Mol Biol 2007; 104: 326-333.
15. Tiganescu A, Walker EA, Hardy RS, Mayes AE, Stewart PM,. Localization, age- and site-dependent expression, and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in skin. J Invest Dermatol 2011; 131: 30-36.
16. Terao M, Murota H, Kimura A, Kato A, Ishikawa A, Igawa K, et al. 11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair. PLoS ONE 2011; 6: e25039.
17. Diederich S, Quinkler M, Burkhardt P, Grossmann C, Bahr V, Oelkers W,. 11Beta-hydroxysteroid-dehydrogenase isoforms: tissue distribution and implications for clinical medicine. Eur J Clin Invest 2000; 30 (Suppl. 3): 21-27.
18. St Jean DJ, Jr, Wang M, Fotsch C,. Inhibitors of 11beta-HSD1: a potential treatment for the metabolic syndrome. Curr Top Med Chem 2008; 8: 1508-1523.
19. Bhat BG, Hosea N, Fanjul A, Herrera J, Chapman J, Thalacker F, et al. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl) -amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J Pharmacol Exp Ther 2008; 324: 299-305.
20. Moore XL, Hoong I, Cole TJ,. Expression of the 11beta-hydroxysteroid dehydrogenase 2 gene in the mouse. Kidney Int 2000; 57: 1307-1312.
21. Stulnig TM, Oppermann U, Steffensen KR, Schuster GU, Gustafsson JA,. Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 2002; 51: 2426-2433.
22. Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, et al. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 2006; 147: 5061-5068.
23. Benavides F, Oberyszyn TM, VanBuskirk AM, Reeve VE, Kusewitt DF,. The hairless mouse in skin research. J Dermatol Sci 2009; 53: 10-18.
24. Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR,. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 2009; 18: 643-649.
25. Walburn J, Vedhara K, Hankins M, Rixon L, Weinman J,. Psychological stress and wound healing in humans: a systematic review and meta-analysis. J Psychosom Res 2009; 67: 253-271.
26. Brogden KA, Guthmiller JM, Salzet M, Zasloff M,. The nervous system and innate immunity: the neuropeptide connection. Nat Immunol 2005; 6: 558-564.
27. Christian LM, Graham JE, Padgett DA, Glaser R, Kiecolt-Glaser JK,. Stress and wound healing. Neuroimmunomodulation 2006; 13: 337-346.
28. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ,. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15; quiz 16-8.
29. Aberg KM, Radek KA, Choi EH, Kim DK, Demerjian M, Hupe M, et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest 2007; 117: 3339-3349.
30. Bitar MS,. Glucocorticoid dynamics and impaired wound healing in diabetes mellitus. Am J Pathol 1998; 152: 547-554.
31. Boscaro M, Barzon L, Fallo F, Sonino N,. Cushing's syndrome. Lancet 2001; 357: 783-791.
32. Choi EH, Brown BE, Crumrine D, Chang S, Man MQ, Elias PM, et al. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol 2005; 124: 587-595.
33. Slominski AT, Botchkarev V, Choudhry M, Fazal N, Fechner K, Furkert J, et al. Cutaneous expression of CRH and CRH-R. Is there a "skin stress response system?" Ann N Y Acad Sci 1999; 885: 287-311.
34. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, et al. Corticotropin releasing hormone and the skin. Front Biosci 2006; 11: 2230-2248.
35. Castinetti F, Conte-Devolx B, Brue T,. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone. Neuroendocrinology 2010; 92 (Suppl. 1): 125-130.
36. McMaster A, Ray DW,. Drug insight: selective agonists and antagonists of the glucocorticoid receptor. Nat Clin Pract Endocrinol Metab 2008; 4: 91-101.
37. Ge R, Huang Y, Liang G, Li X,. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Curr Med Chem 2010; 17: 412-422.
38. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
39. Harno E, White A,. Will treating diabetes with 11beta-HSD1 inhibitors affect the HPA axis? Trends Endocrinol Metab 2010; 21: 619-627.
40. Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, et al. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 2006; 126: 386-392.
41. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR,. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008; 49: 499-509.